Apixaban Dosing for Mesenteric Vein Thrombosis

Initial Treatment and Maintenance

The American College of Cardiology recommends initiating apixaban at 10 mg orally twice daily for 7 days, followed by 5 mg orally twice daily for at least 3 months, for patients with mesenteric vein thrombosis and normal renal function, with consideration for extended anticoagulation depending on whether the thrombosis was provoked or unprovoked 1
For the initial 7-day loading dose regimen, start with apixaban 10 mg orally twice daily, which requires no initial parenteral anticoagulation, as recommended by the American Heart Association 1, 2
Transition to apixaban 5 mg orally twice daily after completing the 7-day loading dose, as suggested by the American College of Chest Physicians 1, 2

For provoked mesenteric vein thrombosis, treat for a minimum of 3 months, as recommended by the American College of Cardiology 1
Consider indefinite anticoagulation for unprovoked mesenteric vein thrombosis or when persistent risk factors remain, as strongly recommended by the American College of Chest Physicians 4, 1

For patients requiring extended anticoagulation beyond 6 months, reduce to apixaban 2.5 mg orally twice daily for secondary prevention, as suggested by the American College of Chest Physicians 4, 1
This reduced dose minimizes bleeding risk while maintaining efficacy for preventing recurrent VTE, with a weak recommendation and very low-certainty evidence from the American College of Chest Physicians 4

Patients on indefinite therapy should be reassessed at least annually to evaluate the risks and benefits of continuing anticoagulation, as recommended by the American College of Chest Physicians 4, 1
Routine laboratory monitoring is not required for apixaban, as it provides predictable anticoagulation at fixed doses, as stated by the American Heart Association 3

Consider indefinite anticoagulation for patients with active malignancy, as recommended by the International Initiative on Thrombosis and Cancer 1
The International Initiative on Thrombosis and Cancer upgraded apixaban to grade 1A recommendation for cancer-associated thrombosis, with starting dose of 10 mg twice daily for 7 days 5

Apixaban has approximately 27% renal elimination, making it favorable in mild to moderate renal impairment, as stated by the American Heart Association 3
Avoid apixaban in severe renal impairment (CrCl <15 mL/min) and use with caution in CrCl <25 mL/min, as recommended by the American College of Cardiology 1, 2

Apixaban is contraindicated in patients with severe hepatic impairment, as stated by the American Heart Association 2
Avoid apixaban in patients with intracranial vascular malformations due to high hemorrhage risk, as recommended by the American College of Cardiology 1